| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 07/10/2008 | CA2671925A1 Sustained-release formulations comprising crystals, macromolecular gels, and particulate suspensions of biologic agents |
| 07/10/2008 | CA2670658A1 Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same |
| 07/10/2008 | CA2660448A1 Chd5 is a novel tumor suppressor gene |
| 07/09/2008 | EP1942190A2 Immoglobulin fusion proteins having modified effector functions and uses thereof |
| 07/09/2008 | EP1942189A2 Method for producing secreted proteins |
| 07/09/2008 | EP1942188A1 Recombinant viral proteins and particles |
| 07/09/2008 | EP1942187A1 Cytokine protein family |
| 07/09/2008 | EP1942186A2 Recombinant platelet collagen receptor glycoprotein VI and its pharmaceutical use |
| 07/09/2008 | EP1942115A1 Agglutinable glp-1 analogue and sustained-release pharmaceutical composition |
| 07/09/2008 | EP1942114A2 Mammalian cytokines; related reagents and methods |
| 07/09/2008 | EP1942113A1 Neuronal differentiation inhibitor peptide and use thereof |
| 07/09/2008 | EP1941909A1 Preventives/remedies for cancer |
| 07/09/2008 | EP1941906A1 Hepatic fibrosis inhibitor |
| 07/09/2008 | EP1941905A1 APO-2 Ligand-anti-her-2 antibody synergism |
| 07/09/2008 | EP1941904A2 Anti-TNF antibodies and methotrexate in the treatment of autoimmune diseases |
| 07/09/2008 | EP1941902A1 Use of Somatostatin analogs in cluster headache |
| 07/09/2008 | EP1941901A1 An exterior-applied formulation and its preparation methods and uses |
| 07/09/2008 | EP1941900A1 Novel exendin agonist compounds |
| 07/09/2008 | EP1941899A1 Agent for promoting glucagon-like peptide 1 secretion, food or drink for promoting glucagon-like peptide 1 secretion, agent for inhibiting postprandial increase in blood sugar level and food or drink for inhibiting postprandial increase in blood sugar level |
| 07/09/2008 | EP1941898A2 Treatment of neuromuscular disorders and conditions with different botulinum serotype |
| 07/09/2008 | EP1941897A2 Dermatological compounds containing oligopeptides for increasing skin sensitivity and neuronal stimulus perception |
| 07/09/2008 | EP1941896A1 Dipeptide-containing composition for oral administration |
| 07/09/2008 | EP1941872A1 Use of TNF-alpha inhibitors for treating nerve root injury |
| 07/09/2008 | EP1941867A1 Prevention and reduction of blood loss |
| 07/09/2008 | EP1941040A1 Modulation of glucocorticoid receptor expression |
| 07/09/2008 | EP1941029A2 Methods of specifying mesodermal, endodermal and mesoendodermal cell fates |
| 07/09/2008 | EP1940880A2 Treating diabetes using inhibitors of il-1 |
| 07/09/2008 | EP1940877A1 Modified biodegradable polymers, preparation and use thereof for making biomaterials and dressings |
| 07/09/2008 | EP1940871A2 Protease-resistant forms of vegf-d, method of making and method of use |
| 07/09/2008 | EP1940870A2 Conserved membrane activator of calcineurin (cmac), a novel therapeutic protein and target |
| 07/09/2008 | EP1940865A2 Novel protein transduction domains and uses therefor |
| 07/09/2008 | EP1940862A2 Allele-specific rna interference |
| 07/09/2008 | EP1940518A1 Milk derived composition and use to enhance muscle mass or muscle strength |
| 07/09/2008 | EP1940471A1 IMPLANTABLE BIOCOMPATIBLE IMMtTNOISOLATORY VEHICLE FOR DELIVERY OF GDNF |
| 07/09/2008 | EP1940469A1 Animal medicament and method of manufature |
| 07/09/2008 | EP1940463A2 Method for enhancing immune responses in mammals |
| 07/09/2008 | EP1940458A1 Compositions for and methods of granzyme b inhibition |
| 07/09/2008 | EP1940457A2 Modified proteases that inhibit complement activation |
| 07/09/2008 | EP1940456A2 Wwox gene, vectors containing the same, and uses in treatment of cancer |
| 07/09/2008 | EP1940455A2 Dietary supplement formulations for improved delivery of coenzyme q10 and methods of administration |
| 07/09/2008 | EP1940454A2 Oral formulation for enteric disorders and/or rehydration |
| 07/09/2008 | EP1940453A2 Therapeutic combination of hamlet and a hdac inhibitor to treat cancer |
| 07/09/2008 | EP1940452A2 Cgrp peptide antagonists and conjugates |
| 07/09/2008 | EP1940451A1 Method of treating pulmonary disease with interferons |
| 07/09/2008 | EP1940450A2 Method of modulation |
| 07/09/2008 | EP1940449A2 Wound-healing pharmaceutical compositions comprising at least one soluble dextran and at least one platelet-derived growth factor |
| 07/09/2008 | EP1940448A2 Pdgf amphiphilic polymer complex |
| 07/09/2008 | EP1940447A1 Treatment of neurodegenerative disorders |
| 07/09/2008 | EP1940446A2 Nogo receptor polypeptides and polypeptide fragments and uses thereof |
| 07/09/2008 | EP1940445A2 Stem cell derived factors for treating pathologic conditions |
| 07/09/2008 | EP1940444A2 Methods of preparing targeted immunoliposomes |
| 07/09/2008 | EP1940442A2 Phosphorylation of tau by abl |
| 07/09/2008 | EP1940441A2 Methods and compositions for the treatment of gastrointestinal disorders |
| 07/09/2008 | EP1940440A2 Methods and compositions for prevention and treatment of diabetic and aged skin |
| 07/09/2008 | EP1940439A1 Reducing post-operative adhesion formation with intraperitoneal glutamine |
| 07/09/2008 | EP1940438A2 Stabilized glp-1 analogs |
| 07/09/2008 | EP1940437A2 Compositions and methods for treating bacteria |
| 07/09/2008 | EP1940436A1 Methods for treating immune mediated neurological diseases |
| 07/09/2008 | EP1940427A2 Encapsulation system |
| 07/09/2008 | EP1940426A1 Composition of whey growth factor extract for reducing muscle inflammation |
| 07/09/2008 | EP1940425A2 Method of treating pancreatitis |
| 07/09/2008 | EP1940424A2 Compositions and methods for the augmentation and repair of defects in tissue |
| 07/09/2008 | EP1940355A2 Drug delivery nanocarriers targeted by landscape phage |
| 07/09/2008 | EP1940348A2 A composition comprising a coupled enzyme system |
| 07/09/2008 | EP1841316A4 Regulation of ccn2 by ccn3 and its therapeutic and diagnostic potential in fibrosis, sclerosis and other diseases |
| 07/09/2008 | EP1755650B1 A biomolecule-containing suspension formulation of increased stability deliverable via an implantable delivery device |
| 07/09/2008 | EP1729794B1 A pharmaceutical composition comprising a non-detergent sulphobetaine |
| 07/09/2008 | EP1727553B1 Agent for substitution of blood plasma and a method of its production |
| 07/09/2008 | EP1715890B1 Ctgf as target for the therapy of microalbuminuria in patients with diabetic nephropathy |
| 07/09/2008 | EP1590666B1 Compositions and methods for enhancing apoptosis |
| 07/09/2008 | EP1583551A4 Composition for preventing the formation of new scar comprising bmp-7 |
| 07/09/2008 | EP1572226B1 Peptides having a high cysteine content |
| 07/09/2008 | EP1523571B1 Sgk and nedd used as diagnostic and therapeutic targets |
| 07/09/2008 | EP1465863B1 Potassium channel modulators |
| 07/09/2008 | EP1448220B1 Pharmaceutical composition comprising an antiphlogistic agent and lactalbuminhydrolysate and the use thereof |
| 07/09/2008 | EP1448211B1 A composition for lowering the concentration of intestinal pathogenic peptides |
| 07/09/2008 | EP1446144B1 The use of leptin in infertility |
| 07/09/2008 | EP1427391B1 Solid-phase agent for vascular occlusion with immobilised platelet binding agent |
| 07/09/2008 | EP1404362B1 Signal-1/signal-2 bifunctional peptide inhibitors |
| 07/09/2008 | EP1403281B1 Novel ligand and dna thereof |
| 07/09/2008 | EP1392348B1 Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists |
| 07/09/2008 | EP1381345B1 Delivery of disease control in aquaculture using yeasts containing bioactive proteins |
| 07/09/2008 | EP1338604B9 N-alkylglycine trimeres capable of protecting neurons against excitotoxic aggressions and compositions containing said trimeres |
| 07/09/2008 | EP1156820B1 Use of vascular endothelial growth factor-2 (vegf-2) |
| 07/09/2008 | EP1019084B1 Novel antimicrobial polypeptide and methods of use |
| 07/09/2008 | EP1017718B1 Novel gene defective in apeced and its use |
| 07/09/2008 | EP0970121B1 Peptide fragments of myelin basic protein, their pharmaceutical compositions and their use in treating multiple sclerosis |
| 07/09/2008 | EP0932674B1 A NOVEL MAMMALIAN GENE, bcl-w, BELONGS TO THE bcl-2 FAMILY OF APOPTOSIS-CONTROLLING GENES |
| 07/09/2008 | EP0832189B2 Process for controlling sialylation of proteins produced by mammalian cell culture |
| 07/09/2008 | EP0804584B2 Sequences of hepatitis c virus genotype 7 and their use as prophylactic, therapeutic and diagnostic agents |
| 07/09/2008 | EP0783577B1 Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors and the use of such compounds in the treatment of neurological disorders and diseases |
| 07/09/2008 | EP0476130B1 Enterically transmitted non-a/non-b hepatitis viral agent and characteristic epitopes thereof |
| 07/09/2008 | CN101218356A Method for identifying skin care composition-resistant skin-binding peptides |
| 07/09/2008 | CN101218344A Method for production of a bioengineered form of tissue plasminogen activator |
| 07/09/2008 | CN101218280A Polymeric derivative of cytidine metabolic antagonist |
| 07/09/2008 | CN101218248A Composition and method for producing stable amyloid beta oligomers of high molecular weight |
| 07/09/2008 | CN101217972A Method for fostering bone formation and preservation |
| 07/09/2008 | CN101217971A Treatment of tumors |
| 07/09/2008 | CN101217970A Compositions, methods and uses for a novel family of peptides |
| 07/09/2008 | CN101217965A Glucose uptake modulator and method for treating diabetes or diabetic complications |